Market Place
Sourcing Support
Invenra Welcomes Dr. Alan J. Korman to Advisory Board
14 Jul 2025 //
BUSINESSWIRE
Invenra Launches T-Body™ Trispecific Platform for Antibodies
13 May 2025 //
BUSINESSWIRE
Invenra Highlights Exelixis Phase 1 Study of XB628 in Solid Tumor
13 May 2025 //
BUSINESSWIRE
Invenra Launches B-Body Express Bispecific Platform
22 Apr 2025 //
BUSINESSWIRE
Invenra, Orion Partner For Bispecific Antibody Cancer Therapy
30 Jan 2025 //
PRESS RELEASE
Invenra Launches Bispecific Antibody Discovery in Four Months
03 Dec 2024 //
BUSINESSWIRE
Invenra Welcomes Three Industry Leaders to Its Board of Directors
17 Sep 2024 //
BUSINESSWIRE
Invenra`s INV724 Gets Rare Pediatric And Orphan Drug Designations For NB
23 Aug 2024 //
BUSINESSWIRE
Invenra Highlights Exelixis` Phase 1 Trial Of XB010 In Advanced Solid Tumors
07 Aug 2024 //
BUSINESSWIRE
Invenra to Present Preclinical Data on INV322
20 Sep 2022 //
BUSINESSWIRE
Exelixis and Invenra expand partnership to develop cancer antibodies
17 Aug 2021 //
PHARMACEUTICALTECHNOLOGY
Exelixis and Invenra Expand Collaboration to Develop Novel Biologics in Oncology
16 Aug 2021 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.